Efficacy of acarbose as monotherapy in NIDDM patients.

Abstract

The efficacy and safety of acarbose (100 mg three times a day for 12 weeks) was investigated in an open study in patients with non-insulin dependent diabetes mellitus who could not achieve satisfactory glycaemic control by diet alone. Acarbose significantly decreased fasting plasma glucose from 165.9 +/- 16.0 mg/dl to 159.5 +/- 16.9 mg/dl (P value < 0.01). The reduction of postprandial plasma glucose was 11.2 per cent and 9.8 per cent for 1 hour and 2 hours respectively. HbAic also significantly decreased from the baseline. The most common side effects were mild to moderate flatulence and abdominal distension. There were no significant changes in body weight, lipid profile and other biochemical parameters. These results indicate that treatment with acarbose is safe and effective in adjunct to dietary therapy for the treatment of NIDDM.

• Authors: C Deerochanawong, S Serirat, P Kornthong
• Journal: Journal of the Medical Association of Thailand = Chotmaihet thangphaet (J Med Assoc Thai) Vol. 79 Issue 2 Pg. 69-75 (Feb 1996) ISSN: 0125-2208 [Print] Thailand
• PMID: 8868016 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Blood Glucose
• Glycoside Hydrolase Inhibitors
• Trisaccharides
• alpha-Glucosidases
• Acarbose

Topics

• Acarbose
• Adult
• Blood Glucose (drug effects)
• Diabetes Mellitus, Type 2 (diagnosis, drug therapy, physiopathology)
• Female
• Glycoside Hydrolase Inhibitors
• Humans
• Treatment Outcome
• Trisaccharides (administration & dosage, therapeutic use)
• alpha-Glucosidases (administration & dosage, therapeutic use)